Delphinus SoftVue Prospective Case Collection - ARM 2

2016-12-01 16:08:22 | BioPortfolio


The SoftVue™ is a whole breast ultrasound system with an automated scanning curvilinear ring‐array transducer that employs UST. It is currently cleared under FDA 510(k) K123209 and K142517 for use as both a B‐mode ultrasonic breast imaging system and color imaging of transmission data (sound speed and attenuation). SoftVue™ is not intended to be used as a replacement for screening mammography.

SoftVue uses non‐ionizing ultrasound energy to generate tomographic image volumes of the whole breast. While the patient lays prone on a padded table with one breast comfortably submerged in a bath of warm water, a ring‐shaped transducer, 22 cm in diameter, encircles the breast and pulses low‐frequency sound waves through the water and into the breast tissue. More than 2000 elements in the curvilinear transducer's 360 degree array emit and receive ultrasound signals to analyze echoes from the breast anatomy in all directions, from the chest wall to the nipple. Not only does SoftVue capture data from the reflection of the sound waves off of tissue boundaries and structures within the breast, but because the transducer surrounds the whole breast, SoftVue also captures signals that are transmitted through the breast. This additional transmission data enhances the visualization of the anatomic structure of the breast tissue and is not currently available in any other commercially marketed breast ultrasound device.

This prospective, multicenter, multi‐arm, clinical case collection program is IRB‐approved and will be conducted in compliance with Good Clinical Practice, the Declaration of Helsinki and all applicable regulatory requirements. Arm 2 aims to collectively enroll up to 1,000 women at a total of up to 8 clinical sites. The design of Arm 2 in this protocol is strictly limited to case collection and is non-interventional; any investigational and/or statistical plans for future analyses will be prepared and registered separately, if they are applicable to the requirements of FDAAA 801.

Arm 2 is limited to the cohort of diagnostic female patients of any breast density composition category, who have been recommended for a breast biopsy (BI-RADS 4 or 5) after diagnostic imaging, or who have confirmed imaging findings. Matched sets of diagnostic imaging and SV exams, from the same patient, demographic information, and clinical outcome data, will be collected during diagnostic workup. Ultrasound characteristics for all types of lesions, whether they are benign or malignant, will be collected as well as objective and subjective breast density composition data. Ultrasound image data may be acquired with modified SoftVue devices, which have passed safety and quality evaluations per Delphinus' quality management system (QMS) and satisfy design change control standards, at select clinical sites in accordance with 21 CFR 812.2 (b), as a routine part of feasibility, validation, and verification testing for engineering and product development purposes.

The exams and clinical data accumulated in this prospective case collection (PCC) protocol will populate a database from which future investigations may be designed for peer reviewed publication, development of user training curricula, building teaching case, and creating new marketing materials for SoftVue.



- SoftVue™ (SV) automated whole breast ultrasound system, 510(k) Cleared for B‐Mode ultrasound breast imaging, manufactured by Delphinus Medical Technologies.

- SoftVue™ with device modifications (software, hardware, user‐interface), safety‐tested for human use to complete feasibility, verification, and validation testing as a routine part of product development and performed in accordance with FDA 21 CFR 812.2 (b), manufactured by Delphinus Medical Technologies.

- Full‐field digital mammography (FFDM), FDA Approved for breast screening and diagnosis, various manufacturers. (If clinically indicated)

- Digital breast tomosynthesis (DBT), FDA Approved for breast screening and diagnosis, various manufacturers.

- Handheld Ultrasound (HHUS), FDA-Cleared for diagnostic breast imaging, various manufacturers. (If clinically indicated)

- Other diagnostic tests and medical device examinations of the breast, including, but not limited to MRI, BSGI, PET, biopsy, and elastography, on the order of a licensed physician, when clinically indicated.


- Primary: To establish a library of cases for use in future SoftVue™ research studies, user training, and marketing.

- Secondary: Determine the frequency and severity of adverse events (AEs) to further evaluate the safety of SoftVue.


From multiple clinical sites whichever comes first:

• Up to 1,000 total enrolled subjects


At least six (≥ 6) qualified clinical sites in the United States

- MQSA Certified

- Digital Breast Tomosynthesis Screening Program Implemented

- Academic, Community Hospital, or Private Practice Setting


- Potential participants will be recruited from the group of women presenting for diagnostic evaluation or biopsy at multiple clinical sites.

- All participants will complete the same standard care diagnostic evaluations that were recommended by a physician

- Eligible patients will receive a SV scan at the time of their scheduled diagnostic appointments, preferably prior to biopsy

- Investigators at the sites will compare SV images to the accompanying diagnostic images and pathology results

- No clinical SV interpretation will be performed and no clinical interventions will be made or changed based on SV images

- All evaluation results, diagnosis and treatment outcomes will be recorded

- Cancer status for all participants will be surveyed from program entry until and including the completion of physician recommended diagnostic workup

- A case will be determined cancer negative if the participant has non-malignant breast biopsy findings or confirmed non-suspicious diagnostic breast imaging findings

- A case will be determined cancer positive if a pathological evaluation confirms a breast cancer diagnosis (malignancy)


- Demographic characteristics (age, race, and ethnicity) and other baseline characteristics (e.g., project arm, project site, breast density, lesion‐specific characteristics) will be tabulated for all participants.

- A flow diagram or table will illustrate patient disposition ("accountability of patient cohort") including reasons for ineligibility and/or unevaluability.

- Safety will be summarized for all enrolled women. With the exception of anticipated events, adverse events (AEs) and serious adverse events (SAEs), occurring from the time of enrollment (SoftVue) and for 24 hours following the conclusion of the SoftVue exam, will be recorded.

- A separate statistical plan will be developed for any future analysis that includes justification of sample size and, if applicable to the requirements of FDAAA 801, will be registered separately in order to share the results.

Study Design

Time Perspective: Prospective


Breast Neoplasms


Non-Interventional, Automated Whole Breast Ultrasound


Lee Breast Center, USC Norris Comprehensive Cancer Center and Hospital
Los Angeles
United States


Enrolling by invitation


Delphinus Medical Technologies, Inc.

Results (where available)

View Results


Published on BioPortfolio: 2016-12-01T16:08:22-0500

Clinical Trials [4924 Associated Clinical Trials listed on BioPortfolio]

Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons

The purpose of this study is to determine whether addition of automated whole breast ultrasound to the usual screening mammography in a population of asymptomatic women with mammographical...

Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging

Brief Summary: The QT Ultrasound system is an automated scanner which transmits pulsed ultrasound plane waves through the breast, as well as collects reflected ultrasound output. As the pa...

Automated Breast Ultrasound Screening

Women with dense breasts (BIRADS 3 or 4) with a BIRADS category 1 or 2 mammogram are asked to participate in a automated volume breast ultrasound scanner. The study evaluates prospectively...

Comparison of Diagnostic Accuracy of Automated Volume Breast Scanner to Hand Held Ultrasound for Diagnostic Breast Exam

Women age >18 scheduled for a diagnostic ultrasound examination had both a hand held ultrasound and an automated breast volume scan. Exams were performed by different technologists. Images...

Detection of Breast Lesions by Automatic Breast US

Mammography is considered the standard imaging method for breast cancer screening, and is known to result in reduced mortality from breast cancer. However, the diagnostic yield of mammogra...

PubMed Articles [7238 Associated PubMed Articles listed on BioPortfolio]

Supplemental Screening With Automated Breast Ultrasound in Women With Dense Breasts: Comparing Notification Methods and Screening Behaviors.

Supplemental screening with ultrasound has been shown to detect additional breast malignancies in women with dense breast tissue and normal mammogram findings. The frequency of supplemental screening ...

Whole-Breast Ultrasound for Breast Screening and Archiving.

The incidence of breast cancer is increasing worldwide, reinforcing the importance of breast screening. Conventional hand-held ultrasound (HHUS) for breast screening is efficient and relatively easy t...

Improved cancer detection in automated breast ultrasound by radiologists using Computer Aided Detection.

To investigate the effect of dedicated Computer Aided Detection (CAD) software for automated breast ultrasound (ABUS) on the performance of radiologists screening for breast cancer.

Enhancing Your Acoustics: Ultrasound Image Optimization of Breast Lesions.

A general understanding of ultrasound physics relative to image optimization is essential when performing breast ultrasound examinations and in accurately interpreting images of the breast. Appropriat...

Sonographic Phenotypes of Molecular Subtypes of Invasive Ductal Cancer in Automated 3-D Breast Ultrasound.

Our aim was to investigate whether Breast Imaging Reporting and Data System-Ultrasound (BI-RADS-US) lexicon descriptors can be used as imaging biomarkers to differentiate molecular subtypes (MS) of in...

Medical and Biotech [MESH] Definitions

Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.

Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.

More From BioPortfolio on "Delphinus SoftVue Prospective Case Collection - ARM 2"

Quick Search

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Searches Linking to this Trial